Ca-AKG: The Longevity Molecule That Declines 10-Fold With Age

← Back to articles

Alpha-ketoglutarate (AKG) is a central TCA cycle intermediate that participates in energy production, amino acid metabolism, collagen synthesis, and epigenetic regulation as a cofactor for DNA and histone demethylases. Human plasma AKG declines roughly 10-fold between age 40 and age 80 — one of the more dramatic age-associated biochemical changes reported. Restoring youthful levels became a testable longevity hypothesis around 2020.

The Mouse Data That Launched the Category

A 2020 study in Cell Metabolism (Asadi Shahmirzadi et al., PMID 32877690) showed that Calcium AKG (CaAKG) supplementation starting at middle age in C57BL/6 mice extended median lifespan in females (the published survival curves correspond to roughly a 10–12% extension) and, more importantly, compressed morbidity: a frailty index fell across multiple aging parameters even when raw lifespan gains were modest. The authors proposed that CaAKG suppresses chronic inflammation in part by inducing IL-10, lowering systemic TNF-α and IL-6.

The First Human Epigenetic Data

A 2021 retrospective open-label analysis in Aging (Demidenko et al., PMID 34847066) examined 42 adults taking Rejuvant® (a formulation of CaAKG plus retinyl palmitate and vitamin D3) for an average of 7 months. Participants showed an average decrease in biological age of 8 years on the TruAge DNA methylation test (p ≈ 6.5×10⁻¹²). Caveats are large: no placebo arm, retrospective selection, and epigenetic age is a biomarker rather than a hard outcome. But the signal generated enough interest to motivate placebo-controlled replication, which is now in progress.

Dosing and Limitations

Common human doses are 1,000–3,000 mg/day of Ca-AKG, typically taken with food. The calcium content is modest but should be counted toward total intake. AKG is not patentable; most products are identical commodity Ca-AKG, and price variation reflects marketing rather than chemistry. AKG is well-tolerated in published trials, but anyone with hypercalcemia or on calcium-restricted diets should discuss use with a clinician.

Realistic Expectations

Ca-AKG is one of the more promising longevity interventions with a plausible mechanism and encouraging early human data, but controlled trials with hard endpoints are still in progress. Treat it as an evidence-accumulating supplement, not a proven longevity therapy. Its best use case is in adults over 50 targeting metabolic and inflammatory markers of aging, alongside exercise, sleep, and protein intake — which still outperform any supplement.